Galectin Therapeutics Inc. (GALT)
Develops drug treatments targeting galectin-3 to fight liver disease and cancer.
$3.39+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-7.1%
The outlook
GALT is trading near the lower end of its 52-week range. Analyst price targets average around 224% above the current price, though coverage appears concentrated. The stock sits mixed relative to its moving averages, with overall sentiment neutral.
What’s behind the score
Price trendMixed vs its moving averages
52-week range27% of the way from its 52-week low to high
Price targetAvg target +224% vs current price
Market cap
$223.3M
52-wk high
$7.13
52-wk low
$2.03
50-day avg
$3.33
200-day avg
$3.69
Trailing P/E
—